New Results
Evolution of kinase polypharmacology across HSP90 drug discovery
View ORCID ProfileAlbert A. Antolin, View ORCID ProfilePaul A. Clarke, Ian Collins, View ORCID ProfilePaul Workman, View ORCID ProfileBissan Al-Lazikani
doi: https://doi.org/10.1101/2020.09.09.288936
Albert A. Antolin
1Department of Data Science, The Institute of Cancer Research, London, SM2 5NG, UK
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
Paul A. Clarke
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
Ian Collins
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
Paul Workman
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
Bissan Al-Lazikani
1Department of Data Science, The Institute of Cancer Research, London, SM2 5NG, UK
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK

Article usage
Posted September 10, 2020.
Evolution of kinase polypharmacology across HSP90 drug discovery
Albert A. Antolin, Paul A. Clarke, Ian Collins, Paul Workman, Bissan Al-Lazikani
bioRxiv 2020.09.09.288936; doi: https://doi.org/10.1101/2020.09.09.288936
Subject Area
Subject Areas
- Biochemistry (8820)
- Bioengineering (6523)
- Bioinformatics (23469)
- Biophysics (11798)
- Cancer Biology (9216)
- Cell Biology (13327)
- Clinical Trials (138)
- Developmental Biology (7440)
- Ecology (11417)
- Epidemiology (2066)
- Evolutionary Biology (15160)
- Genetics (10442)
- Genomics (14050)
- Immunology (9176)
- Microbiology (22170)
- Molecular Biology (8817)
- Neuroscience (47600)
- Paleontology (350)
- Pathology (1429)
- Pharmacology and Toxicology (2492)
- Physiology (3733)
- Plant Biology (8084)
- Synthetic Biology (2221)
- Systems Biology (6039)
- Zoology (1254)